Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping

Background: To overcome the problems of HIV-1 diversity in the development of an effective vaccine, we have designed a universal immunogen HIVconsv utilizing the most conserved regions of the HIV-1 proteome across the major clades.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS research and human retroviruses 2013-11, Vol.29 (11), p.A-64
Hauptverfasser: Borthwick, N, Ahmed, T, Ondondo, B, Hayton, E, Nicosia, A, McMichael, A, Dorrell, L, Hanke, T
Format: Artikel
Sprache:eng
Schlagworte:
Human immunodeficiency virus 1
Retrovirus
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: To overcome the problems of HIV-1 diversity in the development of an effective vaccine, we have designed a universal immunogen HIVconsv utilizing the most conserved regions of the HIV-1 proteome across the major clades.
ISSN:0889-2229